Weight-Loss nasal spray enters early human testing
NCT ID NCT07465965
First seen Mar 13, 2026 · Last updated May 15, 2026 · Updated 8 times
Summary
This early-stage study tests a new nasal spray form of semaglutide (a drug used for weight loss) in 60 overweight or obese adults. The main goal is to check safety and how the drug moves through the body, not yet to prove weight loss. Participants receive a single dose and are monitored closely for side effects and drug levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Frontage Clinical Services, Inc.
RECRUITINGSecaucus, New Jersey, 07094, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.